HUTCHMED (China) Limited - American Depositary Shares — Quarterly Financial Data (NASDAQ:HCM) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Dividends per share — — Dividend yield % — — Payout ratio % — —

Haberler

HUTCHMED 2025 yılı final sonuçlarını 5 Mart’ta açıklayacak

HUTCHMED to announce 2025 final results on March 5

Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should Know

HUTCHMED hisseleri, sovleplenib’in Faz III denemesinde birincil sonlanım noktasına ulaşmasıyla yükseldi

HUTCHMED stock rises after sovleplenib meets primary endpoint in Phase III trial

Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - HUTCHMED (China) (NASDAQ:HCM)

Hutchmed’in sovleplenib ilacı wAIHA denemesinde birincil sonlanım noktasına ulaştı

Hutchmed’s sovleplenib meets primary endpoint in wAIHA trial

Çin, savolitinib’in mide kanserinde öncelikli incelemesini onayladı

China approves priority review for savolitinib in gastric cancer

HUTCHMED’in karaciğer kanseri ilacı Çin’de öncelikli inceleme onayı aldı

China approves priority review for HUTCHMED’s liver cancer drug